EUVIMEDEUVIMED entdecken
Crossref

68Ga-PSMA PET/CT-avid Tumour Volume: A Potential Prognostic Biomarker in Metastatic Hormone Sensitive Prostate Cancer

Greta Beale, Alexander Yuile, Wai-Hoong Chan, Joseph Chan, Andrew Kneebone, George Hruby, Thomas Eade, Alexander Guminski, Adrian Lee, Edward Hsiao, Madeleine Tilley, David L Chan

Annals of Urologic Oncology · 28.06.2026

DOI: 10.32948/auo.2026.04.06 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Urologic Oncology, online erschienen am 28.06.2026. Verfasst von Greta Beale und 11 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA) PET/CT provides sensitive whole-body assessment in prostate cancer, yet the prognostic role of total tumour volume (TTV) is not fully defined in metastatic hormone-sensitive disease and needs further exploration.

Methods

We retrospectively reviewed patients with de novo metastatic prostate cancer undergoing baseline PSMA PET/CT at Royal North Shore Hospital between 2014-2019. TTV was quantified using a standardized Standard Uptake Value (SUV) threshold, and patients were stratified by median TTV. Associations between TTV, progression-free survival (PFS), and overall survival (OS) were assessed using Kaplan–Meier and Cox regression analyses.

Results

Fifty-nine patients were included in the study. Patients in the high-TTV group demonstrated reduced OS but no significant difference in PFS. Higher PSMA-derived TTV correlated with increased prostate-specific antigen (PSA) at diagnosis and higher rates of skeletal related events. Higher SUVmax was not associated with longer PFS or OS, nor was it associated with increased skeletal related events.

Conclusion

Baseline PSMA PET/CT-derived tumour volume is an independent prognostic biomarker in metastatic hormone-sensitive prostate cancer, associated with inferior overall survival. Incorporating TTV into existing risk models may refine patient selection for treatment intensification.

Zitieren

APA

Beale, G., Yuile, A., Chan, W., Chan, J., Kneebone, A., Hruby, G., Eade, T., Guminski, A., Lee, A., Hsiao, E., Tilley, M., & Chan, D. L. (2026). 68Ga-PSMA PET/CT-avid Tumour Volume: A Potential Prognostic Biomarker in Metastatic Hormone Sensitive Prostate Cancer. Annals of Urologic Oncology. https://doi.org/10.32948/auo.2026.04.06

Vancouver

Beale G, Yuile A, Chan W, Chan J, Kneebone A, Hruby G, et al. 68Ga-PSMA PET/CT-avid Tumour Volume: A Potential Prognostic Biomarker in Metastatic Hormone Sensitive Prostate Cancer. Annals of Urologic Oncology. 2026. doi:10.32948/auo.2026.04.06

BibTeX
@article{Beale2026,
  author = {Beale, Greta and Yuile, Alexander and Chan, Wai-Hoong and Chan, Joseph and Kneebone, Andrew and Hruby, George and Eade, Thomas and Guminski, Alexander and Lee, Adrian and Hsiao, Edward and Tilley, Madeleine and Chan, David L},
  title = {68Ga-PSMA PET/CT-avid Tumour Volume: A Potential Prognostic Biomarker in Metastatic Hormone Sensitive Prostate Cancer},
  journal = {Annals of Urologic Oncology},
  year = {2026},
  doi = {10.32948/auo.2026.04.06}
}
Kostenlos starten →